Profile data is unavailable for this security.
About the company
Celyad Oncology SA, formerly Celyad SA is a Belgium-based company. The Company is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The Company's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). It also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).
- Revenue in EUR (TTM)102.00k
- Net income in EUR-8.45m
- Incorporated2007
- Employees12.00
- LocationCelyad Oncology SARue Andre Dumont 9MONT-SAINT-GUIBERT 1435BelgiumBEL
- Phone+32 10394100
- Fax+32 10394141
- Websitehttps://www.celyad.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Destiny Pharma PLC | 0.00 | -6.68m | 11.00m | 19.00 | -- | 1.01 | -- | -- | -0.0624 | -0.0624 | 0.00 | 0.0965 | 0.00 | -- | -- | 0.00 | -60.33 | -54.32 | -67.28 | -59.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 13.02 | -- | 35.39 | -- |
| Wntresearch AB | 0.00 | -3.19m | 11.05m | 2.00 | -- | 3.05 | -- | -- | -9.19 | -9.19 | 0.00 | 4.70 | 0.00 | -- | -- | 0.00 | -89.47 | -100.71 | -103.70 | -123.59 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.65 | -- | -- | -- |
| Bioextrax AB publ | 144.78k | -1.97m | 11.28m | -- | -- | 6.92 | -- | 77.88 | -0.8034 | -0.8034 | 0.0588 | 0.5315 | 0.0686 | -- | 4.96 | -- | -93.29 | -86.39 | -102.02 | -110.84 | 3.62 | -- | -1,360.93 | -2,119.90 | -- | -- | 0.00 | -- | 420.51 | 24.40 | -15.21 | -- | 56.86 | -- |
| Circa Group AS | 1.64m | -6.31m | 11.35m | 17.00 | -- | 0.3771 | -- | 6.90 | -0.6555 | -0.6555 | 0.1683 | 2.79 | 0.0403 | 5.46 | 0.9139 | 1,094,747.00 | -15.46 | -- | -19.96 | -- | 75.64 | -- | -383.72 | -- | 0.7097 | -- | 0.00 | -- | 41.73 | -- | -0.0491 | -- | -- | -- |
| ExpreS2ion Biotech Holding AB | 690.72k | -6.93m | 11.49m | 18.00 | -- | 1.33 | -- | 16.63 | -1.33 | -1.33 | 0.129 | 0.8696 | 0.0821 | -- | 4.87 | 298,730.80 | -82.36 | -63.54 | -113.92 | -75.88 | -132.91 | -1.94 | -1,003.55 | -524.31 | -- | -- | 0.0055 | -- | 43.07 | -0.1561 | 22.94 | -- | 19.90 | -- |
| Addex Therapeutics Ltd | 1.44m | -9.27m | 11.58m | 23.00 | -- | -- | -- | 8.04 | -0.1116 | -0.1357 | 0.0166 | -0.014 | 0.2596 | -- | 8.91 | 59,997.39 | -167.14 | -69.05 | -637.08 | -84.19 | -- | -- | -643.81 | -572.59 | -- | -36.25 | -- | -- | 13.99 | -24.47 | 49.26 | -- | -5.45 | -- |
| Enorama Pharma AB | 59.58k | -3.78m | 11.74m | 5.00 | -- | 5.60 | -- | 197.08 | -1.03 | -1.03 | 0.0163 | 0.4271 | 0.0184 | 0.7583 | 0.6384 | 134,000.00 | -116.48 | -73.56 | -184.45 | -104.85 | -635.07 | 43.36 | -6,338.66 | -557.42 | 0.4626 | -605.70 | 0.02 | -- | -80.17 | -23.71 | -6.15 | -- | -- | -- |
| Toleranzia AB | 0.00 | -560.08k | 11.88m | 7.00 | -- | 0.8748 | -- | -- | -0.0405 | -0.0405 | 0.00 | 0.775 | 0.00 | -- | -- | 0.00 | -4.50 | -7.45 | -4.65 | -7.78 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 11.79 | -- | 63.90 | -- |
| Celyad Oncology SA | 102.00k | -8.45m | 12.01m | 12.00 | -- | 1.91 | -- | 117.79 | -0.3287 | -0.3287 | 0.004 | 0.1522 | 0.0057 | -- | 0.1583 | 8,500.00 | -46.94 | -39.16 | -74.63 | -47.45 | 32.35 | 38.94 | -8,282.35 | -107,726.50 | -- | -156.61 | 0.1437 | -- | -- | -49.53 | 79.36 | -- | -11.95 | -- |
| Acticor Biotech SA | 0.00 | -18.65m | 12.13m | 24.00 | -- | 25.82 | -- | -- | -1.68 | -1.68 | 0.00 | 0.0298 | 0.00 | -- | -- | 0.00 | -145.59 | -- | -297.22 | -- | -- | -- | -- | -- | -- | -9.32 | 0.9504 | -- | -- | -- | -25.94 | -- | -- | -- |
| Bivictrix Therapeutics PLC | 0.00 | -3.01m | 12.19m | 10.00 | -- | 2.92 | -- | -- | -0.0351 | -0.0351 | 0.00 | 0.0429 | 0.00 | -- | -- | -- | -57.64 | -- | -65.12 | -- | -- | -- | -- | -- | -- | -- | 0.069 | -- | -- | -- | -1.92 | -- | -- | -- |
| BIOGENED SA | 23.19m | 1.24m | 12.24m | 204.00 | 9.88 | 1.39 | 5.89 | 0.5277 | 2.17 | 2.17 | 40.55 | 15.44 | 1.23 | 1.95 | 3.86 | 476,591.60 | 6.55 | 3.15 | 10.46 | 4.46 | 67.50 | 68.04 | 5.34 | 3.58 | 0.9303 | 4.17 | 0.3269 | -- | 20.02 | 18.88 | 50.74 | 34.99 | 9.88 | -- |
| Coegin Pharma AB | 0.00 | -2.49m | 12.63m | 0.00 | -- | 10.90 | -- | -- | -2.65 | -2.65 | 0.00 | 0.6403 | 0.00 | -- | -- | -- | -125.24 | -122.02 | -201.53 | -154.70 | -- | -- | -- | -28,466.75 | -- | -170.65 | 0.00 | -- | -- | -- | 20.60 | -- | -- | -- |
| Chill Brands Group PLC | 173.22k | -4.30m | 12.86m | 2.00 | -- | -- | -- | 74.24 | -0.0142 | -0.0142 | 0.0006 | -0.0024 | 0.0319 | 0.0992 | 0.3639 | 73,310.00 | -79.21 | -72.55 | -141.46 | -105.35 | 53.05 | -- | -2,485.30 | -1,625.46 | 0.6499 | -8.48 | 1.17 | -- | -86.73 | -50.89 | 23.50 | -- | -35.95 | -- |
| Vivesto AB | 0.00 | -10.38m | 12.92m | 6.00 | -- | 0.7671 | -- | -- | -0.219 | -0.219 | 0.00 | 0.352 | 0.00 | -- | -- | 0.00 | -44.08 | -- | -47.15 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | 64.80 | -- | -- | -- |
Data as of Jun 25 2024. Currency figures normalised to Celyad Oncology SA's reporting currency: Euro EUR
0.24%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BNP Paribas Asset Management Belgium SAas of 31 May 2024 | 72.64k | 0.18% |
| Gestys SAas of 26 Jan 2024 | 28.00k | 0.07% |
| Iris Finance SAas of 31 Dec 2018 | 0.00 | 0.00% |
Data from 31 Dec 2018 - 20 Jun 2024Source: FactSet Research Systems Inc.
